作者
Qunling Xie,Dan Zhu,Ying Deng,Yijie Xiao,Wenting Shi,Qingyang Gu
摘要
Background Atopic dermatitis (AD) is a chronic skin disease commonly caused by the stimulation of genetic and environmental factors which lead to consistent inflammation, intense itch and discomfort with the pathological characterizations of recurrent eczematous skin lesions of blistering and crusting. Currently, AD affects 230 million people worldwide and results in a great health concern and economic burden.1 2 Limitation of well-characterized animal models for AD disease hinders the identification of relevant therapeutic targets and development of potential drugs in early clinical studies to improve efficacy. Here, we generate a 2,4-dinitrochlorobenzene (DNCB)-induced AD model in rhesus monkeys to better study therapeutic response of potential AD drugs. Methods High concentration DNCB was rubbed on the dorsal skin of rhesus monkeys for sensitization. After 4 weeks, low concentration DNCB was applied on the other dorsal skin of all monkeys for challenge, while the animals of treatment group were applied with tacrolimus or dupilumab. During the study, the general health, trans epidermal water loss (TEWL), and clinical score of the skin were monitored. Skin samples of DNCB-treated areas were isolated and assessed for cytokine expression and histopathology. Blood samples were also collected and analyzed for total IgE antibody level, routine cell blood count, and clinical chemistry. Results Monkeys following repeated DNCB application exhibited severe erythema, oozing, crusting, and marked induration in the dorsal skin, along with gradually increased clinical and TEWL score. The histopathology analysis of DNCB-induced skin lesions showed significant epidermal thickening and highly infiltration of inflammatory cells. In addition, serum IgE levels and mRNA expression of AD-associated cytokines in skin biopsy strongly elevated after DNCB stimulation and demonstrated type-2 immune reactions. For the treatment groups, tacrolimus and dupilumab both relieved the pathological manifestations of AD disease shown as lower degree of defective skin, decreased serum IgE and AD-relevant cytokine levels, as well as reduction of inflammatory cells and keratosis in histopathology. Conclusions In this study, we established an AD NHP model by topically applying DNCB on the dorsal skin of rhesus monkeys, which exhibited AD-like skin lesions with edema and scabs, as well as induction of IgE antibody and cytokines and on-site inflammation in the modelling area. In addition, we proved the great therapeutic effect of tacrolimus and dupilumab in treating the AD symptoms, suggesting that the NHP AD model offer the profound potential for evaluating the efficacy and safety of AD therapeutics. References Afshari Moeina, et al. ‘Unraveling the skin; a comprehensive review of atopic dermatitis, current understanding, and approaches.’ Frontiers in Immunology 2024;15:1361005. 4 Mar. Weidinger Stephan, et al. ‘Atopic dermatitis.’ Nature Reviews. Disease Primers 21 Jun. 2018;4(11). Ethics Approval This study was approved by WuXi AppTec Institutional Animal Care and Use Committee (IACUC) institution’s Ethics Board; approval number 20240105-1.